Effect of Vitamin D Supplementation on Inflammation and Cardiometabolic Risk Factors in Obese Adolescents
Completed · Not applicable · Has a placebo group
Conditions studied: Obesity
In brief
Large studies of children show that over half of the children in the United States of America do not have enough vitamin D stored in their bodies. In children who are overweight or obese, the percentage of children who do not have enough vitamin D is even higher. Vitamin D is essential for the body to maintain normal calcium levels and strong bones. Recent research shows that through the actions of inflammatory markers, levels in the blood that measure inflammation in the body, vitamin D plays many other important roles in the body like helping to regulate the immune system, blood sugar levels, blood pressure, and body fat. The purpose of this study is to determine the effect of vitamin D supplementation on inflammatory markers in obese and overweight adolescents. As a secondary goal, we would like to evaluate cardiometabolic risk factors and the correlation between body mass index, vitamin D stores and inflammatory cytokines. In an observed, randomized controlled trial over 6 months we will provide observed vitamin D supplementation or placebo to healthy obese and overweight adolescents and measure changes in inflammatory markers, lipids, blood pressure, and mean blood sugars. We hypothesize that administration of vitamin D to these patients will improve their inflammatory profile and cardiometabolic risk factors (blood glucose, blood pressure, and lipid profile).
Key facts
- Study ID
- NCT01217840
- Run by
- Stanford University
- People needed
- 40
- Starts
- 2010-09-01
- Expected to finish
- 2012-08-01
- Last updated by the study team
- 2017-11-29
Who can join
Age: 11 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Ages 11 years to 17.99 years old
- BMI: 85 percentile for age and gender
You may not qualify if…
- Patients who currently receive:
- vitamin D supplementation >= 400 IU/day
- daily glucocorticoids or anti-epileptics
- Patients who currently have or history of:
- 25-OH vitamin D level < 10 ng/ml or > 60 ng/ml
- rickets
- diabetes mellitus
- liver or kidney disease
- malabsorptive disorders
- genetic syndromes associated with obesity (i.e. Prader-Willi)
- lactose deficiency or insufficiency
- galactosemia
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.